ES2196007T3 - Especificidad para peptidos sinteticos de los anti-proteina basica de la mielina procedentes del liquido cefalorraquideo en esclerosis multiple. - Google Patents
Especificidad para peptidos sinteticos de los anti-proteina basica de la mielina procedentes del liquido cefalorraquideo en esclerosis multiple.Info
- Publication number
- ES2196007T3 ES2196007T3 ES93908754T ES93908754T ES2196007T3 ES 2196007 T3 ES2196007 T3 ES 2196007T3 ES 93908754 T ES93908754 T ES 93908754T ES 93908754 T ES93908754 T ES 93908754T ES 2196007 T3 ES2196007 T3 ES 2196007T3
- Authority
- ES
- Spain
- Prior art keywords
- mbp
- synthetic peptides
- protein
- residues
- multiple sclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Rehabilitation Therapy (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PROTEINA DE LA MIELINA BASICA HUMANA (H-NBP) TIENE UN PESO MOLECULAR DE 18.5 KD Y CONTIENE 170 RESIDUOS DE AMINOACIDO. SE HAN PRODUCIDO LOS PEPTIDOS SINTETICOS QUE TIENEN UNA LONGITUD QUE OSCILA ENTRE 8 Y 25 RESIDUOS Y QUE CUBREN LA LONGITUD COMPLETA DE LA PROTEINA. SE HA HALLADO QUE LOS ANTICUERPOS PARA LA H-MBP (ANTI-MBP) SON NEUTRALIZADOS POR LOS PEPTIDOS SINTETICOS, QUE CUBREN LA H-MBP DESDE ALREDEDOR DEL RESIDUO (61) DEL AMINOACIDO HASTA ALREDEDOR DEL RESIDUO (106) DEL AMINOACIDO. LOS PEPTIDOS SINTETICOS, QUE CUBREN LOS TERMINALES TANTO DE AMINO (ENTRE LOS RESIDUOS 1 A 63) Y DE CARBOXIDO (ENTRE LOS RESIDUOS 117 Y 162) DE LA H-MBP NO NEUTRALIZAN LOS ANTIMBP PURIFICADOS. CONCORDANTEMENTE, DE LOS PEPTIDOS SINTETICOS SELECCIONADOS DE LA MBP PUEDE USARSE COMO TRATAMIENTO PARA LA ESCLEROSIS MULTIPLES NEUTRALIZANDO LOS ANTI-MBP.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002053799A CA2053799C (en) | 1991-10-22 | 1991-10-22 | Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2196007T3 true ES2196007T3 (es) | 2003-12-16 |
Family
ID=4148603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES93908754T Expired - Lifetime ES2196007T3 (es) | 1991-10-22 | 1992-10-15 | Especificidad para peptidos sinteticos de los anti-proteina basica de la mielina procedentes del liquido cefalorraquideo en esclerosis multiple. |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0610446B1 (es) |
AT (1) | ATE236193T1 (es) |
AU (1) | AU2750092A (es) |
CA (1) | CA2053799C (es) |
DE (1) | DE69232987T2 (es) |
DK (1) | DK0610446T3 (es) |
ES (1) | ES2196007T3 (es) |
FI (1) | FI111050B (es) |
NO (1) | NO310513B1 (es) |
NZ (1) | NZ244807A (es) |
RU (1) | RU2121850C1 (es) |
WO (1) | WO1993008212A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817629A (en) * | 1991-10-22 | 1998-10-06 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
US6252040B1 (en) * | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
EP0787147A1 (en) * | 1994-10-25 | 1997-08-06 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
CA2205532A1 (en) | 1994-11-18 | 1996-05-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein |
US6251396B1 (en) | 1994-11-18 | 2001-06-26 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
US6379670B1 (en) | 1994-11-18 | 2002-04-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
US6329499B1 (en) * | 1994-11-18 | 2001-12-11 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
WO1996028470A2 (en) * | 1995-03-09 | 1996-09-19 | Neurocrine Biosciences, Inc. | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis |
CA2201841C (en) * | 1997-04-04 | 2010-01-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
WO2005009455A1 (fr) * | 2003-07-29 | 2005-02-03 | Terentiev Alexandr Alexandrovi | Composition de peptides presentant une propriete immunoregulatrice |
CN102781465A (zh) | 2009-10-12 | 2012-11-14 | 生命生物实验室有限公司 | 用于治疗多发性硬化的组合物 |
US9326773B2 (en) | 2012-01-26 | 2016-05-03 | Covidien Lp | Surgical device including buttress material |
WO2024094562A1 (en) * | 2022-11-01 | 2024-05-10 | Universität Zürich | Novel mbp peptides and their use in the treatment of multiple sclerosis |
-
1991
- 1991-10-22 CA CA002053799A patent/CA2053799C/en not_active Expired - Lifetime
-
1992
- 1992-10-15 WO PCT/CA1992/000448 patent/WO1993008212A1/en active Search and Examination
- 1992-10-15 DE DE69232987T patent/DE69232987T2/de not_active Expired - Lifetime
- 1992-10-15 DK DK93908754T patent/DK0610446T3/da active
- 1992-10-15 RU RU94027578A patent/RU2121850C1/ru not_active IP Right Cessation
- 1992-10-15 AT AT93908754T patent/ATE236193T1/de not_active IP Right Cessation
- 1992-10-15 ES ES93908754T patent/ES2196007T3/es not_active Expired - Lifetime
- 1992-10-15 EP EP93908754A patent/EP0610446B1/en not_active Expired - Lifetime
- 1992-10-15 AU AU27500/92A patent/AU2750092A/en not_active Abandoned
- 1992-10-20 NZ NZ244807A patent/NZ244807A/xx not_active IP Right Cessation
-
1994
- 1994-04-19 NO NO19941415A patent/NO310513B1/no not_active IP Right Cessation
- 1994-04-21 FI FI941860A patent/FI111050B/fi active
Also Published As
Publication number | Publication date |
---|---|
FI941860A (fi) | 1994-04-21 |
DE69232987D1 (de) | 2003-05-08 |
DE69232987T2 (de) | 2004-01-29 |
RU94027578A (ru) | 1996-10-20 |
NO941415L (es) | 1994-06-22 |
FI111050B (fi) | 2003-05-30 |
NZ244807A (en) | 1997-08-22 |
CA2053799A1 (en) | 1993-04-23 |
AU2750092A (en) | 1993-05-21 |
WO1993008212A1 (en) | 1993-04-29 |
NO310513B1 (no) | 2001-07-16 |
EP0610446A1 (en) | 1994-08-17 |
ATE236193T1 (de) | 2003-04-15 |
FI941860A0 (fi) | 1994-04-21 |
CA2053799C (en) | 2002-03-12 |
NO941415D0 (no) | 1994-04-19 |
DK0610446T3 (da) | 2003-07-14 |
RU2121850C1 (ru) | 1998-11-20 |
EP0610446B1 (en) | 2003-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2196007T3 (es) | Especificidad para peptidos sinteticos de los anti-proteina basica de la mielina procedentes del liquido cefalorraquideo en esclerosis multiple. | |
DE68916932D1 (de) | Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus. | |
ES2178000T3 (es) | Composiciones y metodos para tratar infecciones usando analogos de indolicidina. | |
ATE415173T1 (de) | Pan dr-bindeproteinen zur erhöhung der immunantwort | |
GB2255093A (en) | Hiv-1 core protein fragments | |
HUT62916A (en) | Process for producing immunogenic peptides and pharmaceutical compositions comprising same | |
DK0789709T3 (da) | Peptidspecificitet af anti-myelin basisprotein og administrationen af myelin basisproteinpeptider til dissemineret sklerose patienter | |
IL116559A0 (en) | Chimeric proteins | |
NO832904L (no) | Nytt polypeptid, virkning paa immunsystemet, fremgangsmaate til dens isolering og rensning, dets anvendelse, midler inneholdende dette, samt dets spaltningsprodukt, deres anvendelse og middel inneholdende disse | |
NO994806D0 (no) | Peptidfragmenter av myelin basisprotein, deres farmasöytiske preparater og deres anvendelse for Õ behandle multippel sklerose | |
DE3162674D1 (en) | A purified polypeptide, a process for its preparation, its use and pharmaceutical compositions containing it | |
MX9201665A (es) | Composicion farmaceutica para el tratamiento de infecciones del virus de inmunodeficiencia humana del tipo 1 en mamiferos. |